Sarepta Therapeutics (SRPT) Current Assets (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Current Assets of $2.3 billion for Q1 2026, down 5.04% year-over-year from $2.4 billion in Q1 2025, and down 8.99% quarter-over-quarter from $2.5 billion in Q4 2025.
Sarepta Therapeutics (SRPT) Current Assets (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Current Assets history runs 17 years deep, the most recent figure standing at $2.3 billion for Q1 2026.
- In Q1 2026, Current Assets fell 5.04% year-over-year to $2.3 billion; the TTM figure through Mar 2026 stood at $2.3 billion (down 5.04% YoY), while the FY2025 annual figure was $2.5 billion, down 17.42% from the prior year.
- Current Assets for Q1 2026 stood at $2.3 billion, down from $2.5 billion in the prior quarter.
- The five-year high for Current Assets was $3.1 billion in Q4 2024, with the low at $2.3 billion in Q1 2026.
- The 5-year median for Current Assets is $2.5 billion (2025), against an average of $2.6 billion.
- The sharpest annual moves came in 2022 and 2025: Current Assets advanced 20.16% in 2022, then decreased 17.42% in 2025.
- Sarepta Therapeutics' Current Assets stood at $2.6 billion in 2022, then climbed by 0.84% to $2.6 billion in 2023, then increased by 19.16% to $3.1 billion in 2024, then decreased by 17.42% to $2.5 billion in 2025, then slipped by 8.99% to $2.3 billion in 2026.
- Business Quant data shows SRPT's Current Assets at $2.3 billion in Q1 2026, $2.5 billion in Q4 2025, and $2.7 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | 2.22 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.22 Bn |
| Mar 31, 2026 | 2.31 Bn |
| Dec 31, 2025 | 2.54 Bn |
| Sep 30, 2025 | 2.72 Bn |
| Jun 30, 2025 | 2.66 Bn |
| Mar 31, 2025 | 2.43 Bn |
| Dec 31, 2024 | 3.07 Bn |
| Sep 30, 2024 | 2.69 Bn |
| Jun 30, 2024 | 2.68 Bn |
| Mar 31, 2024 | 2.46 Bn |
| Dec 31, 2023 | 2.58 Bn |
| Sep 30, 2023 | 2.45 Bn |
| Jun 30, 2023 | 2.47 Bn |
| Mar 31, 2023 | 2.49 Bn |
| Dec 31, 2022 | 2.56 Bn |
| Sep 30, 2022 | 2.63 Bn |
| Jun 30, 2022 | 2.47 Bn |
| Mar 31, 2022 | 2.53 Bn |
| Dec 31, 2021 | 2.60 Bn |
| Sep 30, 2021 | 2.19 Bn |